Copied to clipboard!
Multi-omic signatures in multiple myeloma
Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma-cell malignancy. Quadruplet therapy, combining anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors, and dexamethasone, is now the standard induction treatment for newly diagnosed multiple myeloma (NDMM). To gain a comprehensive view of molecular changes in MM and their association with treatment response in this new standard care, we performed a multi-omic study of 423 NDMM from the MIDAS trial.
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000002250 | Illumina NovaSeq X | 204 | |
| EGAD50000002251 | Illumina NovaSeq X | 44 | |
| EGAD50000002252 | Illumina NovaSeq X | 120 | |
| EGAD50000002482 | Illumina NovaSeq X | 214 | |
| EGAD50000002483 | Illumina NovaSeq X | 250 | |
| EGAD50000002687 | 207 | ||
| EGAD50000002688 | Illumina NovaSeq X | 55 | |
| EGAD50000002807 | Illumina NovaSeq X | 189 |
